Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
Although multiple sclerosis (MS) is considered to be a CD4, Th17-mediated autoimmune disease, supportive evidence is perhaps circumstantial, often based on animal studies, and is questioned by the perceived failure of CD4-depleting antibodies to control relapsing MS. Therefore, it was interestingly...
Main Authors: | David Baker, Monica Marta, Gareth Pryce, Gavin Giovannoni, Klaus Schmierer |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-02-01
|
Series: | EBioMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396417300452 |
Similar Items
-
Adoptive Transfer of Regulatory T Cells as a Promising Immunotherapy for the Treatment of Multiple Sclerosis
by: Samuel S. Duffy, et al.
Published: (2019-10-01) -
The Future of Immunotherapy: A 20-Year Perspective
by: David C. Wraith
Published: (2017-11-01) -
Update on immunopathogenesis and immunotherapy in multiple sclerosis
by: Selter RC, et al.
Published: (2013-04-01) -
Peptide immunotherapy in experimental autoimmune encephalomyelitis
by: Stephen M Anderton
Published: (2015-06-01) -
Antigen-based immunotherapy for autoimmune disease: current status
by: Hirsch DL, et al.
Published: (2014-12-01)